402 related articles for article (PubMed ID: 8359577)
1. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat.
Stevens MJ; Lattimer SA; Kamijo M; Van Huysen C; Sima AA; Greene DA
Diabetologia; 1993 Jul; 36(7):608-14. PubMed ID: 8359577
[TBL] [Abstract][Full Text] [Related]
2. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
Gillon KR; Hawthorne JN; Tomlinson DR
Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
[TBL] [Abstract][Full Text] [Related]
4. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
Tomlinson DR; Moriarty RJ; Mayer JH
Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
[TBL] [Abstract][Full Text] [Related]
5. Increased nerve polyol levels in experimental diabetes and their reversal by Sorbinil.
Whiting PH; Ross IS
Br J Exp Pathol; 1988 Oct; 69(5):697-702. PubMed ID: 3143396
[TBL] [Abstract][Full Text] [Related]
6. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
Mayer JH; Tomlinson DR
Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
[TBL] [Abstract][Full Text] [Related]
7. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
Hotta N; Kakuta H; Fukasawa H; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K
Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
[TBL] [Abstract][Full Text] [Related]
8. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
9. Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy.
Finegold D; Lattimer SA; Nolle S; Bernstein M; Greene DA
Diabetes; 1983 Nov; 32(11):988-92. PubMed ID: 6416910
[TBL] [Abstract][Full Text] [Related]
10. Aldose reductase gene expression and osmotic dysregulation in cultured human retinal pigment epithelial cells.
Stevens MJ; Henry DN; Thomas TP; Killen PD; Greene DA
Am J Physiol; 1993 Sep; 265(3 Pt 1):E428-38. PubMed ID: 8214052
[TBL] [Abstract][Full Text] [Related]
11. Action of sorbinil in diabetic peripheral nerve. Relationship of polyol (sorbitol) pathway inhibition to a myo-inositol-mediated defect in sodium-potassium ATPase activity.
Greene DA; Lattimer SA
Diabetes; 1984 Aug; 33(8):712-6. PubMed ID: 6086432
[TBL] [Abstract][Full Text] [Related]
12. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes.
Lowitt S; Malone JI; Salem AF; Korthals J; Benford S
Metabolism; 1995 May; 44(5):677-80. PubMed ID: 7752919
[TBL] [Abstract][Full Text] [Related]
13. Sorbitol, inositol and nerve conduction in diabetes.
Gillon KR; Hawthorne JN
Life Sci; 1983 Apr; 32(17):1943-7. PubMed ID: 6835015
[TBL] [Abstract][Full Text] [Related]
14. An aldose reductase inhibitor but not myo-inositol blocks enhanced polyphosphoinositide turnover in peripheral nerve from diabetic rats.
Berti-Mattera L; Day N; Peterson RG; Eichberg J
Metabolism; 1996 Mar; 45(3):320-7. PubMed ID: 8606638
[TBL] [Abstract][Full Text] [Related]
15. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
Kato N; Mizuno K; Makino M; Suzuki T; Yagihashi S
Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717
[TBL] [Abstract][Full Text] [Related]
16. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
Schmidt RE; Plurad SB; Sherman WR; Williamson JR; Tilton RG
Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038
[TBL] [Abstract][Full Text] [Related]
17. Effect of treating streptozotocin-induced diabetic rats with sorbinil, myo-inositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve.
Coppey LJ; Gellett JS; Davidson EP; Dunlap JA; Yorek MA
Int J Exp Diabetes Res; 2002; 3(1):21-36. PubMed ID: 11900277
[TBL] [Abstract][Full Text] [Related]
18. Essential fatty acid treatment--effects on nerve conduction, polyol pathway and axonal transport in streptozotocin diabetic rats.
Tomlinson DR; Robinson JP; Compton AM; Keen P
Diabetologia; 1989 Sep; 32(9):655-9. PubMed ID: 2477293
[TBL] [Abstract][Full Text] [Related]
19. Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2',5'-dioxospiro-[chroman-4,4'-imidazolidine]-2-carbox amide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats.
Kato N; Mizuno K; Matsubara A; Nakano K; Kurono M; Yagihashi S
J Diabetes Complications; 1994; 8(1):27-32. PubMed ID: 8167384
[TBL] [Abstract][Full Text] [Related]
20. Altered neuroexcitability in experimental diabetic neuropathy: effect of acetyl-L-carnitine.
Malone JI; Lowitt S; Corsico N; Orfalian Z
Int J Clin Pharmacol Res; 1992; 12(5-6):237-41. PubMed ID: 1301404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
